|LEOPOLD I Trial: Adolescents and Adults1,2|
Multinational, open-label, prospective trial evaluating pharmacokinetics, efficacy, safety, and perioperative management of bleeding with KOVALTRY®Previously treated male patients (PTPs) aged 12–65 years with severe hemophilia A (<1% FVIII) (N=73) studied for 1 year
Dosing regimens were determined by the investigators to meet individual patients' needs
2x/week prophylaxis: 20–50 IU/kg (n=18)3x/week prophylaxis: 20–50 IU/kg (n=44)
|Primary efficacy endpoint||Annualized bleed rate (ABR) at 12 months (n=62 for efficacy analysis)|
The Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease (LEOPOLD) is a 3-part clinical trial program designed to evaluate the pharmacokinetics, efficacy, and safety of KOVALTRY® in patients with severe hemophilia A.
KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:
On-demand treatment and control of bleeding episodes
Perioperative management of bleeding
Routine prophylaxis to reduce the frequency of bleeding episodes
KOVALTRY® is not indicated for the treatment of von Willebrand disease.
IMPORTANT SAFETY INFORMATION
KOVALTRY® is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.
Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY®. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY® if symptoms occur and seek immediate emergency treatment.
KOVALTRY® may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.
Neutralizing antibody (inhibitor) formation can occur following administration of KOVALTRY®. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.
Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.
Catheter-related infections may occur when KOVALTRY® is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.
The most frequently reported adverse reactions in clinical trials (≥3%) were headache, pyrexia, and pruritus.
For additional important risk and use information, please see full Prescribing Information.
References: 1. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2016. 2. Data on file. Bayer HealthCare Pharmaceuticals, Inc; 2016.
You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
© 2018 Bayer. All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.
Advate is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
Site Last Modified 2/2018
This information contained in this section is intended for US healthcare professionals only.
Click the appropriate link below.
Are you sure you want to leave the KOVALTRY® website?
Bayer is not responsible for the content viewed on other websites.